This invention is related to the area of pharmacology. In particular, it relates to cancer therapeutics.
Central nervous system (CNS) cancers are difficult to treat because most systemically administered therapeutics fail to reach effective concentrations in intracranial tumors (1). This is partially explained by the blood-brain barrier (BBB). In the CNS, the BBB exists along all capillaries consisting of tight junctions thereby blocking large and hydrophilic molecules from passing to the CNS tissues. It is estimated that only about 2% of small-molecule drugs are able to effectively cross the BBB (2).
Mebendazole (MBZ) has been safely used as an antiparasitic in humans for over four decades and displays efficacy against intracranial helminthic infections. We recently demonstrated MBZ preclinical efficacy in orthotopic glioma and medulloblastoma rodent models (3, 4). MBZ significantly reduced tumor growth and improved survival of brain tumor-bearing mice. Based on these results, a Phase I clinical trial with a dose escalation of MBZ for newly diagnosed high-grade glioma patients has been initiated (NCT01729260). Evidence has been generated supporting several anti-cancer mechanisms for MBZ, including tubulin-binding, kinase inhibition anti-angiogenesis and pro-apoptosis (3-8). However, the important features of MBZ's brain penetration and pharmacokinetics remain to be determined. This understanding is important to potentially improve the clinical use of MBZ.
MBZ is highly hydrophobic and can form three different polymorphs based on crystallization conditions (9). The polymorphs A, B and C (MBZ-A, B and C) displayed distinct features in solubility, toxicity and therapeutic effects in anthelmintic applications (10-12). The difference in anti-tumor efficacy of the three polymorphs has not yet been investigated, however, this information might be crucial to future MBZ cancer therapies, since drug formulations might contain various polymorphs in different amounts or combinations. Another critical reason for further investigation is that polymorph C, the most efficacious polymorph in anthelmintic use, can transform over time to the less effective polymorph A, especially with higher temperatures and humidity (13). Since the polymorphs only exist in the solid form and MBZ is exclusively an oral drug, studying the relevant anti-tumor properties of different polymorphs is best accomplished by determining bioavailability and efficacy in animal models via oral administration of MBZ polymorphs. There is a continuing need in the art to identify more effective, more consistent, and safer therapeutics for treating cancers, in particular brain cancers.
According to one aspect of the invention a pharmaceutical formulation of mebendazole is provided. At least 90% of the mebendazole in the formulation is polymorph C, and the formulation is granulated.
According to another aspect of the invention a pharmaceutical formulation of mebendazole is provided that comprises polymorph C and an inhibitor of P-glycoprotein.
According to another aspect of the invention a pharmaceutical formulation that comprises mebendazole and a non-steroidal anti-inflammatory drug (NSAID) is provided.
Another aspect of the invention is a method of administering a pharmaceutical mebendazole formulation. The pharmaceutical mebendazole formulation can be a granulated formulation in which at least 90% of the mebendazole in the formulation is polymorph C, or it can be a combination formulation of polymorph C and an inhibitor of P-glycoprotein, or it can be a formulation of mebendazole comprising polymorph C and an NSAID. According to the method, the formulation is applied to a food prior to ingestion of the food.
According to still another aspect of the invention a method is provided to monitor anti-cancer potency of a mebendazole pharmaceutical formulation. A pharmaceutical formulation comprising mebendazole is assayed, and the amount of polymorph C and amount of polymorph A are determined.
Another aspect of the invention is a method of treating a tumor or reducing the risk of developing a tumor in a human. A pharmaceutical formulation of mebendazole, whether a granulated formulation in which at least 90% of the mebendazole is polytnorph C, or a combination formulation of polymorph C and an inhibitor of P-glycoprotein, or a combination formulation of polymorph C and an NSAID, is administered or dispensed to a human for oral ingestion. The human either has a tumor or is at elevated risk of developing a tumor.
An additional aspect of the invention is a kit for treating tumors or reducing the risk of developing tumor(s). The kit comprises (a) mebendazole (optionally comprising polymorph C) and (b) an inhibitor of P-glycoprotein or an NSAID.
Yet another aspect of the invention is a method of treating a tumor in a human or reducing the risk of developing a tumor. Mebendazole (optionally comprising polymorph C) and either an inhibitor of P-glycoprotein or an NSAID are administered or dispensed to the human for oral ingestion.
These and other embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with tools for combatting highly refractory cancers.
The inventors have developed efficacious and safe formulations for treating tumors, particularly tumors of the brain, breast, and lung. Other tumors may also be treated including but not limited to colorectal, ovarian, sarcomas, gastric, esophageal, prostate, pancreatic, liver, and thyroid tumors.
Polymorph C of mebendazole has been found to be the most potent of the polymorphs for treating tumors. Often, however, it appears that the potency of a preparation decreases over time due to loss of polymorph C or conversion to other polymorphs. Preferably a preparation of mebendazole that is used in the invention will be at least 90% polymorph C. In some cases it may be at least 91%, 92%, 93%, 94%, 93%, 96%, 97%, 98%, or 99% polymorph C. The mebendazole may optionally be granulated. This provides a suitable formulation for adding to comestibles and providing a palatable medicament. It may also increase gastric absorption. Optionally the granulated form may be coated. This may increase the palatability of the medicament. Typical materials used for enteric coatings include fatty acids, waxes, shellac, plastics, and plant fibers. Any such enteric coatings used in the art may be used.
P-glycoprotein (P-gp), the permeability glycoprotein or plasma glycoprotein is an active, efflux, membrane bound transport protein pump. It is a member of ATP binding cassette (ABC) super family. It goes by many names including ABCB1, MDR1, PGY1, and CD243. It is involved in multidrug resistance in tumors. In that context it may be referred to as a multidrug resistant pump. Any inhibitor of P-gp can be used in formulations with mebendazole, including but not limited to elacridar, progesterone, gomasin A, piperine, apocyanin, amprenavir, quinidine, and valspodar. The P-gp inhibitor may be co-coated along with the mebendazole or the P-gp inhibitor may be uncoated or separately coated. The two agents may be administered at the same time, in combination or separately. The two agents may be delivered within days or weeks of each other as part of a combined regimen.
In some formulations and for some uses, such as prophylactic uses, polymorph C can be formulated with a non-steroidal anti-inflammatory drug. These include, without limitation, Aspirin, Choline and magnesium salicylates, Choline salicylate, Celecoxib, Dielofenac potassium, Dielofenac sodium, Dielofenac sodium with misoprostol, Diflunisal, Etodolac, Fenoprofen calcium, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Magnesium salicylate, Meclofenamate sodium, Mefenamic acid, Meloxicam, Nabumetone, Naproxen, Naproxen sodium, Oxaprozin, Piroxicam Rofecoxib, Salsalate, Sodium salicylate, Sulindac, Tolmetin sodium, and Valdecoxib. The combination is potent in prophylactic effect.
Individuals who have higher risk of developing colorectal cancer are those with any of a variety of environmental, behavioral, and genetic factors. These include, without limitation, overweight or obese, physical inactivity, a diet that is high in red meats (such as beef, pork, lamb, or liver) and processed meats, smoking, heavy alcohol use, personal history of colorectal polyps or colorectal cancer, personal history of inflammatory bowel disease, family history of colorectal cancer or adenomatous polyps, family cancer syndromes, familial adenomatous polyposis (FAP), Lynch syndrome, attenuated FAP, Turcot syndrome, Peutz-Jeghers syndrome, MUTYH-associated polyposis, and type 2 diabetes. These individuals may benefit from the prophylaxis with mebendazole, in particular with polymorph C, and more particularly with combination therapies of mebendazole and non-steroidal anti-inflammatory drugs. The two agents may be administered at the same time, in combination or separately. The two agents may be delivered within days or weeks of each other as part of a combined regimen of prophylaxis. A racemic mixture of mebendazole or even a composition comprising more of polymorphs A or B than C may be used for prophylactic and/or therapeutic anti-cancer treatments.
Application of a formulation to food may encompass any means known in the art. Sprinkling, shaking, spraying, dowsing, or mixing, for example, can be used to apply the formulation to the food. Administration or dispensing of a formulation for oral ingestion may comprise, for example, delivering in a cup, on a plate, or directly into the mouth of the subject.
Brain tumors which may be treated include Astrocytoma; Atypical Teratoid Rhaboid Tumor (ATRT); Chondrosarcoma; Choroid Plexus; Craniopharyngioma; Cysts; Ependymoma; Germ Cell Tumor; Glioblastoma; Glioma; Hemangioma; Lipoma; Lymphoma; Medulloblastoma; Meningioma; Metastatic Brain Tumor; Neurofibroma; Neuronal & Mixed Neuronal-Glial Tumors; Oligoastrocytoma; Oligodendroglioma; Pineal Tumors; Pituitary Tumors; PNET; and Schwannoma.
Human tumors which may be treated with the formulations include Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Adolescents, Cancer in; Adrenocortical Carcinoma; Childhood; AIDS-Related Cancers; Kaposi Sarcoma; Lymphoma; Anal Cancer; Appendix Cancer; Astrocytomas, Childhood; Atypical Teratoid/Rhabdoid Tumor, Childhood, Central Nervous System; Basal Cell Carcinoma—see Skin Cancer (Nonmelanoma); Childhood; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Childhood; Bone Cancer; Ewing Sarcoma Family of Tumors; Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor; Astrocytomas, Childhood; Brain and Spinal Cord Tumors Treatment Overview, Childhood; Brain Stem Glioma, Childhood; Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors, Childhood; Central Nervous System Germ Cell Tumors, Childhood; Craniopharyngioma, Childhood; Ependymoma, Childhood; Breast Cancer; Childhood; Male; Pregnancy, Breast Cancer and; Bronchial Tumors, Childhood; Burkitt Lymphoma—see Non-Hodgkin Lymphoma; Carcinoid Tumor; Childhood; Gastrointestinal; Carcinoma of Unknown Primary; Childhood; Cardiac (Heart) Tumors, Childhood; Central Nervous System; Atypical Teratoid/Rhabdoid Tumor, Childhood; Embryonal Tumors, Childhood; Germ Cell Tumor, Childhood; Lymphoma, Primary; Cervical Cancer; Childhood; Childhood Cancers; Chordoma, Childhood; Chronic Lymphocytic Leukemia (CLL); Chronic Myelogenous Leukemia (CML); Chronic Myeloproliferative Neoplasms; Colon Cancer; Colorectal Cancer; Childhood; Craniopharyngioma, Childhood; Cutaneous T-Cell Lymphoma—see Mycosis Fungoides and Sézary Syndrome; Duct, Bile, Extrahepatic; Ductal Carcinoma In Situ (DCIS); Embryonal Tumors, Central Nervous System, Childhood; Endometrial Cancer; Ependymoma, Childhood; Esophageal Cancer; Childhood; Esthesioneuroblastoma, Childhood; Ewing Sarcoma; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer; Intraocular Melanoma; Retinoblastoma; Fallopian Tube Cancer—see Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer; Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Childhood; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumors (GIST); Childhood; Germ Cell Tumor; Central Nervous System, Childhood; Extracranial, Childhood; Extragonadal; Ovarian; Testicular; Gestational Trophoblastic Disease; Glioma—see Brain Tumor; Childhood Brain Stem; Hairy Cell Leukemia; Head and Neck Cancer; Childhood; Heart Cancer, Childhood; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin Lymphoma; Hypopharyngeal Cancer; Ilntraocular Melanoma; Islet Cell Tumors, Pancreatic Neuroendocrine Tumors; Kaposi Sarcoma; Kidney; Renal Cell; Wilms Tumor and Other Childhood Kidney Tumors; Langerhans Cell Histiocytosis; Laryngeal Cancer; Childhood; Leukemia; Acute Lymphoblastic (ALL); Acute Myeloid (AML); Chronic Lymphocytic (CLL); Chronic Myelogenous (CML); Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer (Primary); Childhood; Lung Cancer; Childhood; Non-Small Cell; Small Cell; Lymphoma; AIDS-Related; Burkitt—see Non-Hodgkin Lymphoma; Cutaneous T-Cell—see Mycosis Fungoides and Sézary Syndrome; Hodgkin; Non-Hodgkin; Primary Central Nervous System (CNS); Macroglobulinemia, Waldenström; Male Breast Cancer; Malignant Fibrous Histiocytoma of Bone and Osteosarcoma; Melanoma; Childhood; Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma, Malignant; Childhood; Metastatic Squamous Neck Cancer with Occult Primary; Midline Tract Carcinoma Involving NUT Gene; Mouth Cancer; Multiple Endocrine Neoplasia Syndromes, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Myelogenous Leukemia, Chronic (CML); Myeloid Leukemia, Acute (AML); Myeloma, Multiple; Myeloproliferative Neoplasms, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Childhood; Neuroblastoma; Non-Hodgkin Lymphoma; Non-Small Cell Lung Cancer; Oral Cancer; Childhood; Oral Cavity Cancer, Lip and; Oropharyngeal Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Childhood; Epithelial; Germ Cell Tumor; Low Malignant Potential Tumor; Pancreatic Cancer; Childhood; Pancreatic Neuroendocrine Tumors (Islet Cell Tumors); Papillomatosis, Childhood; Paraganglioma; Childhood; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pharyngeal Cancer; Pheochromocytoma; Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma, Childhood; Pregnancy and Breast Cancer; Primary Central Nervous System (CNS) Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Childhood; Sarcoma; Ewing; Kaposi; Osteosarcoma (Bone Cancer); Rhabdomyosarcoma; Soft Tissue; Uterine; Sézary Syndrome; Skin Cancer; Childhood; Melanoma; Merkel Cell Carcinoma; Nonmelanoma; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma—see Skin Cancer (Nonmelanoma); Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Childhood; T-Cell Lymphoma, Cutaneous—see Mycosis Fungoides and Sézary Syndrome; Testicular Cancer; Childhood; Throat Cancer; Thymoma and Thymic Carcinoma; Childhood; Thyroid Cancer; Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Unknown Primary, Carcinoma of; Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Childhood; Vulvar Cancer; Waldenström Macroglobulinemia; and Wilms Tumor.
Kits are means of packaging two or more items in a single container. The kit may comprise multiple internal containers to keep components separate. The kit may comprise instructions or other printed matter to facilitate use, such as standard curves. Information may also be provided on an electronic storage medium such as a disk or drive. Information may be provided by reference to a website. Additional components that are useful for treating cancers may also be provided. Tools for administration may be included. Vessels for mixing components may be provided in the kit.
Mebendazole can be prepared by any means known in the art. In one method, p-chlorotoluene is used as a starting material. See
In this study, we demonstrate that MBZ can reach the brain tissue in significant concentrations and with high brain to plasma ratios. Between 1 and 8 hours after the oral administration, MBZ-C maintained the brain levels above 0.767 μg/g (equivalent to 2.7 μM), with a Cmax of 2,016 μg/g (equivalent to 7.1 μM). These exceeded the IC50 (4.3 μM) of MBZ on VEGFR2 kinase in vitro and the IC50 (0.11-1 μM) in a series of glioma and medulloblastoma cell lines in tissue culture (3,4). Furthermore, MBZ-C emerged as the most efficient polymorph, achieving an ACU0-24 h B/P ratio of 0.82. This is encouraging since temozolomide, the standard treatment for high-grade gliomas, was measured of having a B/P ratio of 0.408 in mice and a cerebrospinal fluid (CSF)/plasma ratio of 0.2 in human (21,22). In our study, the distributions of MBZ in the GL261 brain tumor and in the normal brain tissue did not differ significantly. It is worth mentioning that advanced growth of GL261 glioma results in substantial amount of blood in the tumor, similarly to other glioma models and a thorough perfusion was essential to eliminate the contamination of MBZ from the blood.
Among the three polymorphs, MBZ-A showed no efficacy in GL261 glioma model, explained by the very low plasma presence at only 19% of AUC0-24 h measured with MBZ-C. MBZ-A's low bioavailability and inferior anti-tumor efficacy are in line with previous reports of its poor performance in anti-parasitic applications (10,12). In comparison, MBZ-B was able to reach 165% of MBZ-C's AUC0-24 h in the plasma, while showing a similar brain concentration demonstrated by the measurement at 6 h. This could explain the elevated toxicity of MBZ-B in GL261 glioma-bearing mice as the anti-brain tumor efficacy remained essentially the same compared to MBZ-C. Thus, we suggest that MBZ-C is a better choice in brain tumor therapy. As a practical matter, the tablets made by MBZ-C should be stored under lower temperature (13), since the MBZ tablets of Teva brand may have lost its efficacy under the standard RT condition within 3 years likely due to the conversion to polymorph A, although we do not know the original concentration of polymorph C in these tablets that used to be efficacious in our previous study (3).
MBZ's small size (295 daltons) and lipophilic property favor brain penetration (2). It is remarkable that other benzimidazoles tested so far, such as albendazole, thiabendazole, flubendazole, oxifendazole and fenbendazole sharing similar physical properties, failed or only marginally improved the survival of GL261 glioma-bearing mice, even at higher doses than MBZ (Supplementary
P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette (ABC) transporter and plays an important role in limiting drug uptake into the brain. (23) Elacridar is a 3rd generation inhibitor of P-gp efflux transporters and also inhibits the breast cancer-resistant protein (BCRP, ABCG2) that is another key efflux transporter in BBB (24). Previous studies demonstrated that co-administration of elacridar in rodents has markedly increased by multiple folds the brain distribution of a number of cancer drugs, such as sunitinib, pazopanib, erlotinib and crizotinib, which were determined as the substrates of P-gp and ABCG2 by in vitro and animal studies (25-28). Furthermore, elacridar has been found safe in Phase I clinical trials (19). In this study, we investigated the combination of elacridar with MBZ to potentially enhance its therapeutic efficacy. We found that the combination greatly improved the survival in two orthotopic brain tumor models. However, in this limited study, the B/P ratio and brain AUC0-8 h of MBZ did not show statistically significant differences with co-administration of elacridar, despite its ability to significantly increase survival in brain cancer bearing mice. When analyzing the metabolites, MBZ-NH2, one of the two major metabolites in rodents and human (20), was significantly elevated in terms of B/P ratio (2.5 folds) and AUC0-8 h (2.4 folds) as a result of co-administration of elacridar. Also noticeable is our finding that MBZ-N2 was preferentially accumulated in the GL261 brain tumor vs the normal brain tissues. Although these data could indicate that MBZ-NH2 is a potential substrate of P-gp and/or ABCG2, the significance of this finding is unclear at this point. A possible direct cytotoxic effect of MBZ-NH2 appears unlikely as further testing displayed only a marginal cytotoxicity with cultured GL261 cells. However, increased toxicity through MBZ-NH2's preferential accumulation in the acidic tumor environment cannot be excluded and requires further investigations. Further investigations include the study of MBZ and elacridar interactions, particularly the potential substrate profile of efflux transporters with MBZ, in order to better understand and thereby improve the combination with MBZ.
MBZ-C is the most efficacious polymorph in brain tumor therapy. The combination of MBZ-C with elacridar, a p-glycoprotein inhibitor, can greatly improve efficacy. This combination may be used to treat, inter alia, high grade glioma and/or medulloblastoma. The combination may be co-administered or separately administered as part of a regimen of treatment.
The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.
MBZ tablets (500 mg) from Janssen Pharmaceuticals (Pantelmin®) and Medley Pharmaceuticals were purchase from local pharmacies in Brazil in 2013 and stored at −20° C. freezer. MBZ tablets (100 mg) from Teva Pharmaceuticals USA were purchased from the Outpatient Pharmacy at the Johns Hopkins Hospital in 2011 and stored at room temperature (RT). Teva has discontinued MBZ in the US market since Oct. 2011. Aurochem Laboratories LTD. (Mumbai, India) manufactured MBZ tablets (500 mg) S2015 containing the current active pharmaceutical ingredient (API) that typically has mixed polymorphs, and S2017 (polymorph C) with specific API revealed. Aurochem also kindly supplied us with MBZ polymorph A, B and C. Elacridar (ELD; GF120918; N-(4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide)) was purchased from Sigma (St. Louis, Mo., USA). Thiabendazole (TBZ), flubendazole (FLZ), oxifendazole (OXZ) and fenbendazole (FBZ) were purchased from Sigma (St. Louis, Mo., USA).
Cell lines for this study were obtained as previously described: mouse glioma cell line GL261 and the human medulloblastoma xenograft D425Med (D425). (3,14) GL261 and D425 cells were maintained in DMEM media supplemented with 10% fetal bovine serum and antibiotics at 37° C. in humidified air containing 5% CO2. GL261-luc cells expressing firefly luciferase were described previously (3).
A Direct Detect™ infrared (IR) spectrometer was used (Millipore, Billerica, Mass., USA). MBZ powder or tablets ground to powder was mixed with water first, applied to the card and air dried following the manufacturer's instructions. The spectra of —C═O and —NH were analyzed and compared as described before. (9)
All animal studies were approved by the Animal Care and Use Committee (ACUC) of the Johns Hopkins University. The intracranial implantation of GL261-luc in the frontal lobe and D425 cells in the cerebellum of the mouse brain followed the procedure described before (3,4). Five days after tumor implantation, mice were gavaged with MBZ or the other benzimidazoles at 50 mg/kg five days a week. MBZ and other benzimidazoles were prepared by either mixing the power with PBS and sesame oil (1:1, v:v) (Sigma) or by grinding the tablets to powder and resuspending in the aforementioned PBS/sesame oil mixture. Elacridar was prepared as a 10 mg/ml suspension in 0.5% hydroxypropylmethylcellulose and 0.5% Tween 80 in PBS similarly as described before (15).
Female C57BL6 mice, 5-6 weeks of age, were purchased from NCl. Animal experimentation was conducted under an approved IACUC protocol and complied with local and national guidelines. All MBZ polymorphs and tablets were administered by oral gavage at a dose of 50 mg/kg. Elacridar was administered by oral gavage at 50 mg/kg 2 hours prior to the administration of MBZ-C. Mice (3 animals/time point) were first anesthetized via intraperitoneal injection of 60 μl of a stock solution containing ketamine hydrochloride (75 mg/kg) (100 mg/ml; Ketamine HCl; Abbot Laboratories, Chicago, Ill., USA) and xylazine (7.5 mg/kg) (100 mg/ml; Xyla-ject®, Phoenix Pharmaceutical, St. Joseph, Mo., USA) in a sterile 0.9% NaCl solution. Then the blood samples were taken by puncturing and aspiring from the left heart ventricle. Blood samples were mixed with 5 mM EDTA and centrifuged at 10000 g for 5 min to obtain the plasma for further analysis.
For brain distribution studies, mice were perfused under anesthesia with 20 ml ice-cold saline supplemented with 20 μl of 0.02% heparin by injecting slowly into the left heart ventricle using a 20 gauge needle. The right atrium was cut open before to allow the blood outflow. The yellow color of kidney indicated a good perfusion quality that was essential to deplete blood from the brain tissue. In GL261 tumor-bearing mice, GL261 tumor was distinguished from the normal brain by easily recognizable differences in color and shade. GL261 tumor was separated with a scalpel and the normal brain tissue was cut from the contralateral hemisphere. All brain samples were weighed and stored at −80° C. before processing.
Blood, brain and brain tumor tissues were harvested as a function of time after MBZ administration. To compare the pharmacokinetics of MBZ polymorphs, three cohorts of mice each were administered a single dose of 50 mg/kg by oral gavage. For the initial comparison studies, plasma samples were obtained at 1, 2.5, 4, 6, 8, 15, and 24 hours after MBZ administration while brain tissue was only collected at 6 hours. For the comparison studies of polymorph C with or without ELD, plasma and brain tissue samples were obtained at 2.5, 4, and 8 hours after MBZ administration. Brain tumor tissue samples were also obtained for polymorph C alone.
MBZ and the two metabolites, 2-amino-5-benzoyl-benzimidazole (MBZ-NH2, CAS 52329-60-9) and rac dihydro mebendazole (MBZ-OH, CAS 60254-95-7), were quantified in plasma, brain and brain tumor tissue. Tissue homogenates were prepared at a concentration of 200 mg/ml in plasma prior to extraction. Mebendazole and metabolites were extracted from 50 μl of plasma or tissue homogenates with 0.1 ml of methanol containing 0.5 μg/ml of the internal standard A620223.69. After centrifugation, the supernatant (60 μl) was mixed with water (40 μl) and then transferred into autosampler vials. Separation was achieved with an Atlantis dC18 (2.1×100 mm, 3 μm) column at room temperature with methanol/water mobile phase (60:40, v:v) containing 0.1% formic acid using isocratic flow at 0.25 ml/min for 5 minutes. The analytes were monitored using an AB Sciex triple quadrapole™ 5500 mass-spectrometric detector (Applied Biosystems, Foster City, Calif., USA) using electrospray ionization operating in positive mode. The spectrometer was programmed to allow the [MH+] ions of MBZ, MBZ-NH2, MBZ-OH, and A620223.69 at m/z 296.0, 238.0, 298.0, and 287.2, respectively to pass through the first quadrupole (Q1) and into the collision cell (Q2). The daughter ions for MBZ (m/z 263.9), MBZ-NH2 (m/z 105.1), MBZ-OH (m/z 266.0), and A620223.69 (m/z 124.1) were monitored through the third quadrupole (Q3). Calibration curves for MBZ and metabolites were computed using the area ratio peak of the analysis to the internal standard by using a quadratic equation with a 1/x weighting function over the range of 5 to 500 ng/ml (MBZ) and 1 to 500 ng/ml (metabolites) with dilutions of up to 1:100 (v:v). If one or more concentrations were below limits of quantification, a value of ½ the limit of quantification was assigned for pharmacokinetic calculations. If two consecutive time points were below limits of quantification, the last one was excluded from the analysis.
Mean plasma and brain concentrations were calculated at each time point for both MBZ and its metabolites. 1.045 g/ml was used as the average wet rodent brain tissue density (16). Pharmacokinetic parameters were calculated from mean MBZ and its metabolites concentration-time data using noncompartmental methods as analyzed in Phoenix® WinNonlin® version 6.3 (Pharsight Corp., Mountain View, Calif.). Cmax and Tmax were the observed values from the mean concentration data. The AUClast was calculated using the log-linear trapezoidal method. λz was determined from the slope of the terminal phase of the concentration-time profile. The terminal half-life (T1/2) was determined by dividing 0.693 by λz. If the r2 of λz was <0.9, the T1/2 was not reported. Relative systemic exposure to MBZ was calculated using the AUClast: Metabolites AUClast/MBZ AUClast. Relative systemic exposure in brain or brain tumor compared with plasma was calculated using the AUClast: Brain or Brain Tumor AUClast/Plasma AUClast.
Animal survival data were analyzed by GraphPad Prism 5.0. The p-values were determined by a Mantel-Cox test. A p-value under 0.05 was accepted as statistically significant.
For the pharmacokinetic studies comparing the polymorphs or administration with ELD, the Method of Bailer was used to estimate the variance of AUClast given the calculated variance of the mean concentration at each time point (17). This was then followed by a pairwise comparison using a Z-test to determine whether there was a significant difference between MBZ exposure as expressed by AUClast (18). Comparisons of individual data were conducted using the nonparametric Wilcoxon signed rank test with post-hoc analysis using an All Pairs Tukey-Kramer test. The level of significance was P<0.05.
We examined the polymorph content of several commercially available tablets (Janssen, Medley and Teva) and two made to order tablets (Aurochem S2015 used the current API that typically has mixed polymorphs and S2017 was specified as pure MBZ-C) by comparing their IR profiles with the individual MBZ polymorphs (
MBZ-A appeared to be ineffective in treating intracranial GL261 glioma-bearing mice, while MBZ-C displayed the best efficacy (
Following an oral dosing of 50 mg/kg, MBZ-C achieved a plasma AUC0-24 h of 16,039 h*ng/ml (
We determined the plasma levels of the major metabolites MBZ-NH2 and MBZ-OH of MBZ polymorphs (P<0.05 for AUC0-24 h of MBZ-NH2 with MBZ-B>C>A; P<0.05 for AUC0-24 h of MBZ-OH with MBZ-B and C>A; Table 1A). The levels of MBZ-C's metabolites in plasma and brain generally followed the same pattern of MBZ-C's concentration (
Combination of MBZ with Elacridar
Achieving a sufficient therapeutic concentration in the tumor and the surrounding brain tissue is a critical challenge that is faced by almost all brain cancer therapies. Four hours after oral administration, we found MBZ-C brain concentration peaked at 2,016 ng/g (equivalent to 7.1 μM) (Table 1A), which was well above the IC50S of cultured glioma and medulloblastoma cells (0.11-1 μM) and also above MBZ's inhibitory IC50 with VEGFR2 kinase at 4.3 μM in vitro (3,4). The relatively high brain concentration might help explain MBZ efficacy in brain tumor models. Next, we reasoned that a further increase in the brain distribution of MBZ would be desirable as it may increase therapeutic efficacy. Aside from a pure mechanical barrier, the BBB employs active efflux mechanisms to limit drug entry such as P-glycoprotein (P-gp). Elacridar (ELD) is a potent third-generation inhibitor that inhibits P-gp as well as breast cancer resistance protein (BCRP) and co-administration of elacridar has increased the brain penetration of several drugs (15,19). We first examined the cytotoxicity of elacridar in GL261 mouse glioma cells and determined the IC50 to be 5.8 μM (
Combination with Elacridar Improved the Treatment of MBZ
Combination therapy of elacridar and MBZ increased the survival benefit in GL261 syngeneic glioma and D425 xenograft medulloblastoma models (
A prolonged treatment course with elacridar and MBZ was attempted, however, increased toxicity such as severe weight loss and mortality limited those studies (data not shown).
The disclosure of each reference cited is expressly incorporated herein.
This invention was made with government support under R25NS065729 awarded by National Institute of Neurological Disorders and Stroke, and P30 -CA006973, UL1-RR025005 and 1S10RR026824-01 from the National Institutes of Health. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2016/016968 | 2/8/2016 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62112706 | Feb 2015 | US |